Overview

A Study to Investigate the Use of Golimumab (Simponi®) in Participants With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis (P06554)

Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
This is a study to assess the use of golimumab (Simponi®) in participants with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. The study objective is to evaluate the clinical safety of golimumab (Simponi®) under real-life, clinical practice conditions as assessed by the incidence and type of (serious) adverse events and changes in clinical status of participants as assessed by clinical parameters.
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Antibodies, Monoclonal
Golimumab
Methotrexate